Initial report on the month 12 results from PSoHO for biologic-treated patients with moderate-to-severe psoriasis in the real-world setting

被引：0
|
作者：
Costanzo, Antonio [1 ]
Paul, Carle F. [2 ]
Carrascosa, Jose Manuel [3 ]
Tada, Yayoi [4 ]
Brnabic, Alan [5 ]
Schuster, Christopher [5 ,6 ]
Reed, Catherine [5 ]
Abrahamy, Michael [5 ]
Riedl, Elisabeth [5 ,6 ]
Pinter, Andreas [7 ]
Boecker, Ulrike [8 ]
机构：
[1] Humanitas Res Hosp, Div Dermatol, Milan, Italy
[2] Univ Paul Sabatier Toulouse III, Touluse, France
[3] Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Barcelona, Spain
[4] Teikyo Univ, Dept Dermatol, Sch Med, Tokyo, Japan
[5] Eli Lilly & Co, Indianapolis, IN USA
[6] Med Univ Vienna, Dept Dermatol, Vienna, Austria
[7] Univ Hosp Frankfurt, Clin Dermatol Venereol & Allergol, Frankfurt, Germany
[8] Lilly Deutschland GmbH, Bad Homburg, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P091
引用
收藏
页码：70 / 70
页数：1
相关论文
共 50 条
  • [1] Initial report on the Month 12 results from the Psoriasis Study of Health Outcomes (PSoHO) for patients with moderate-to-severe psoriasis treated with biologics in the real-world setting
    Costanzo, Antonio
    Paul, Carle
    Carrascosa, Jose Manuel
    Tada, Yayoi
    Brnabic, Alan
    Schuster, Christopher
    Reed, Catherine
    Abrahamy, Michael
    Riedl, Elisabeth
    Pinter, Andreas
    Mahar, Patrick
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 26 - 26
  • [2] Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting
    Lynde, Charles
    Riedl, Elisabeth
    Maul, Julia-Tatjana
    Torres, Tiago
    Pinter, Andreas
    Fabbrocini, Gabrielle
    Daniele, Flavia
    Brnabic, Alan
    Reed, Catherine
    Wilhelm, Stefan
    Holzkamper, Thorsten
    Schuster, Christopher
    Puig, Luis
    ADVANCES IN THERAPY, 2023, 40 (03) : 869 - 886
  • [3] Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting
    Charles Lynde
    Elisabeth Riedl
    Julia-Tatjana Maul
    Tiago Torres
    Andreas Pinter
    Gabrielle Fabbrocini
    Flavia Daniele
    Alan Brnabic
    Catherine Reed
    Stefan Wilhelm
    Thorsten Holzkämper
    Christopher Schuster
    Luis Puig
    Advances in Therapy, 2023, 40 : 869 - 886
  • [4] Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab
    Cazana, Tamara Gracia
    Monroig, Josep Riera
    Izu, Rosa
    Yanguas, Ignacio
    Espes, Marta Lorda
    Salas, Maria Pilar Sanchez
    Gil, Miguel Fernando Garcia
    Bielsa, Alba Navarro
    Manrique, Beatriz Aldea
    Blasco, Manuel Almenara
    de Aranibar, Francisco Javier Garcia-Latasa
    Fuentelsaz, Victoria
    Callaghan, Ana Morales
    Ara-Martin, Mariano
    JAAD INTERNATIONAL, 2024, 16 : 66 - 71
  • [5] Ixekizumab treatment in patients with moderate-to-severe plaque psoriasis in a real-world clinical setting
    Ogut, Neslihan Demirel
    Yildirim, Sema Koc
    Erbagci, Ece
    Hapa, Fatma Asli
    JOURNAL OF COSMETIC DERMATOLOGY, 2022, 21 (11) : 6215 - 6224
  • [6] Real-world evidence of oral roflumilast in patients with moderate-to-severe psoriasis
    Gyldenlove, Mette
    Nissen, Christoffer Valdemar
    Stave, Sascha Dinsen Wreschner
    Thomsen, Simon Francis
    Egeberg, Alexander
    Loft, Nikolai
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [7] Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month 12 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHO
    Riedl, Elisabeth
    Pinter, Andreas
    Zaheri, Shirin
    Costanzo, Antonio
    Brnabic, Alan
    Konicek, Bruce
    McKenzie, Robert
    Lampropoulou, Anastasia
    Rayes, Mohamed El
    Haustrup, Natalie
    Schuster, Christopher
    DERMATOLOGY AND THERAPY, 2024, 14 (05) : 1327 - 1335
  • [8] Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)
    Pinter, Andreas
    Eyerich, Kilian
    Costanzo, Antonio
    Garrelts, Alyssa
    Schuster, Christopher
    Mert, Can
    Lampropoulou, Anastasia
    Fotiou, Konstantinos
    Maul, Julia-Tatjana
    Papp, Kim A.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
  • [9] Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year
    Galluzzo, Marco
    Talamonti, Marina
    Bernardini, Nicoletta
    Chiricozzi, Andrea
    De Simone, Clara
    Bonifati, Claudio
    Bruni, Pierluigi
    Diotallevi, Federico
    Esposito, Maria
    Graceffa, Dario
    Hansel, Katharina
    Loconsole, Francesco
    Moretta, Gaia
    Mugheddu, Cristina
    Papini, Manuela
    Richetta, Antonio
    Skroza, Nevena
    Atzori, Laura
    Fargnoli, Maria Concetta
    Persechino, Severino
    Offidani, Annamaria
    Stingeni, Luca
    Peris, Ketty
    Potenza, Concetta
    Bianchi, Luca
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (12) : 1585 - 1592
  • [10] Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events
    Gulliver, Wayne
    Penney, Michelle
    Power, Rebecca
    Gulliver, Susanne
    Montmayeur, Sonia
    Burge, Russel
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (01) : 354 - 360
12345